跳至主要内容
临床试验/EUCTR2008-000084-41-FR
EUCTR2008-000084-41-FR进行中(未招募)1 期

A multi-center open label extension study of HGT-1111 (Recombinant Human Arylsulfatase A or rhASA) treatment in patients with Late Infantile Metachromatic Leukodystrophy (MLD)

Shire Human Genetic Therapies Inc0 个研究点目标入组 11 人开始时间: 2009年8月5日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
11

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. The patient's legally authorized guardian(s) must provide signed informed consent prior to the performance of any study-related activities. (Study-related activities are any procedures that would not have been performed during normal management of the subject).
  • 2. Completion of study HGT-MLD-048
  • 3. The patient and his/her guardian(s) must have the ability to comply with the clinical protocol.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1. Spasticity so severe that it inhibiits the patient from being transported to the treatment site.
  • 2. Presence of known clinically significant cardiovascular, hepatic, pulmonary or renal disease or any other medical condition that, in the opinion of the investigator, would preclude participatioin in the trial.
  • 3. Any other medical condition or serious intercurrent illness or extenuating circumstance that, in the opinion of the Investigator, would preclude participation in the trial.

研究者

相似试验

进行中(未招募)
1 期
A multi-center open label extension study of HGT-1111 (Recombinant Human Arylsulfatase A or rhASA) treatment in patients with Late Infantile Metachromatic Leukodystrophy (MLD)Metachromatic Leukodystrophy (MLD) in late infantile patientsMedDRA version: 9.1Level: LLTClassification code 10024381Term: Leukodystrophy
EUCTR2008-000084-41-DKShire Human Genetic Therapies Inc11
进行中(未招募)
1 期
A multi-center open label extension study of HGT-1111 (Recombinant Human Arylsulfatase A or rhASA) treatment in patients with Late Infantile Metachromatic Leukodystrophy (MLD)
EUCTR2008-000084-41-BEShire Human Genetic Therapies Inc11
进行中(未招募)
1 期
A Multi-center, Open-Label Extension Study of HGT-1111 (Recombinant Human Arylsulfatase A or rhASA) Treatment in Patients with Late Infantile Metachromatic Leukodystrophy (MLD) - ND
EUCTR2008-000084-41-ITShire Human Genetic Therapies Inc11
进行中(未招募)
不适用
A Multicenter Open-Label Study of Gene-Activated Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Patients with Type 1 Gaucher Disease Previously Treated with Imiglucerase - ND
EUCTR2006-006304-11-ITSHIRE HUMAN GENETIC THERAPIES, INC.40
进行中(未招募)
1 期
A multicenter open-label study of Gene-Activated Human Glucocerebrosidase (GA-GCB) enzyme replacement therapy in patients with type 1 Gaucher disease previously treated wiht imiglucerase. - TKT034Type I Gaucher DiseaseMedDRA version: 9.1Level: LLTClassification code 10018048Term: Gaucher's disease
EUCTR2006-006304-11-DEShire Human Genetic Therapies Inc40